首页> 外文期刊>Therapeutic delivery >Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease
【24h】

Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease

机译:壳聚糖纳米颗粒作为新型药物载体的设计和评估,该药物用于传递卡巴拉汀用于治疗阿尔茨海默氏病

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: The objective of the study was to develop chitosan nanoparticles of the drug rivastigmine and to study the effect of polysorbate 80 coating on its biodistribution. Results: Chitosan nanoparticles containing rivastigmine were prepared by spontaneous emulsification. The mean size of the particles was 47 +- 4 nm. zeta, potential analysis demonstrated a positive charge for the particles and coating with polysorbate 80 slightly reduced the surface charge of the particles. A biphasic release pattern was observed for the release of drug from the nanoparticles. Release of the drug from nanoparticles was diffusion controlled and the mechanism of drug release was Fickian. Conclusion: The biodistribution studies demonstrated that coating of nanoparticles with 1% polysorbate 80 altered the uptake of nanoparticles by different organs.
机译:目的:该研究的目的是开发药物卡巴拉汀的壳聚糖纳米颗粒,并研究聚山梨酯80涂层对其生物分布的影响。结果:通过自发乳化制备了含有rivastigmine的壳聚糖纳米粒子。颗粒的平均尺寸为47±4nm。 ζ电势分析表明,该颗粒带正电荷,用聚山梨酯80涂层稍微降低了颗粒的表面电荷。观察到从纳米颗粒释放药物的双相释放模式。药物从纳米颗粒的释放受到扩散控制,药物释放的机制是菲克。结论:生物分布研究表明,用1%的聚山梨酯80包覆纳米颗粒可改变不同器官对纳米颗粒的吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号